28/02/2026
EMBARK establece la enzalutamida más ADT como nuevo estándar de atención para el cáncer de próstata de alto riesgo BCR.
🌞Dra. Maria Jose Lopez Espinoza
Oncologia clinica
Previa cita 8475-5256
León y Chinandega
At the 2025 European Society for Medical Oncology (ESMO) Congress, Dr. Stephen Freedland presented the definitive overall survival (OS) results of the phase III EMBARK trial. This landmark study addressed a pivotal question in the management of prostate cancer: whether intensifying standard androgen deprivation therapy (ADT) with the androgen receptor signaling inhibitor could improve survival in men with high-risk biochemically recurrent (BCR) disease following local therapy.
A total of 1,068 patients with high-risk BCR were enrolled. Inclusion criteria required a PSA doubling time (PSADT) of ≤9 months and a PSA level ≥1 ng/mL after radical prostatectomy or ≥2 ng/mL above nadir after radiotherapy, with no evidence of metastasis on conventional imaging. Patients were randomized 1:1:1 to receive enzalutamide (160 mg daily) plus leuprolide, enzalutamide monotherapy, or leuprolide plus placebo. A unique feature of the trial was the treatment suspension protocol: if PSA was undetectable (
